Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07782333

A Study Evaluating TRIV-573 in Atopic Dermatitis

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.

Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).

The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has Atopic Dermatitis.
  • Has moderate to severe, active and symptomatic atopic dermatitis.

Exclusion criteria

  • Severe or uncontrolled medical conditions.
  • Use of prohibited medications within stated washout periods.

Treatment and study plan

TRIV-573

Drug

TRIV-573 (Subcutaneous injection)

Placebo

Drug

Placebo (Matching Placebo subcutaneous injection)

Primary outcomes

  1. Percentage of participants with improvement of AD

    Time frame: Baseline through Week 16

Secondary outcomes

  1. Percentage of participants with improvement of AD

    Time frame: Baseline through Week 16

  2. Percentage of participants with TEAEs

    Time frame: Baseline through Week 36

  3. Serum concentration of TRIV-573

    Time frame: Baseline through Week 36

  4. Percentage of participants with anti-TRIV-573 antibodies

    Time frame: Baseline through Week 36

Study contacts

Contact information is provided by the study sponsor or research team.

Triveni Bio, Inc

CONTACT

[email protected]

+1 (781) 472-2230

Sponsors and collaborators

Lead sponsor

Triveni Bio

Industry

Registry information

Official study title

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 24, 2026
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.